Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A healthy male or female adult 20-25 years of age (≥20 years of age and ≤25 years of age) at the time of vaccination;~* Free of obvious health problems as established by medical history and physical examination before entering into the study;~* Written informed consent obtained from the subject;~* Able to read the Subject Information Sheet and Consent Form;~* Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study;~* females must be of non-childbearing potential, i.e. surgically sterilized or, if of childbearing potential, she must be abstinent or on adequate contraceptive precautions (i.e. intrauterine contraceptive device; oral contraceptives or other equivalent hormonal contraception, e.g. progestin implantable, cutaneous hormonal patch or injectable contraceptives) for 30 days prior to vaccination, have a negative pregnancy test within 48 hours prior to vaccination and must agree to continue such precautions for 60 days after completion of the vaccination series~Exclusion Criteria:~* Pregnant or lactating female, planning to become pregnant or planning to discontinue abstinence or contraceptive precautions;~* History of any neurological or behavioral disorder or seizures, with the exception of a single febrile seizure in childhood;~* History of drug abuse or alcohol consumption (more than 2 drinks per day);~* History of allergic disease/reaction likely to be exacerbated by any component of the vaccine;~* Acute or chronic, pulmonary, cardiovascular, hepatic, renal, hematologic or endocrine functional defect, as determined by physical examination or laboratory tests;~* Any confirmed or suspected immunosuppressive or immunodeficient condition or seropositive for HBsAg, anti-HCV or anti-HIV;~* Acute disease at the time of enrollment (acute disease is defined as the presence of a moderate or severe illness with or without fever);~* Chronic hepatomegaly, right upper quadrant abdominal pain or tenderness;~* Chronic splenomegaly, left upper quadrant abdominal pain or tenderness;~* Hypertension; chest pain, palpitations, dizziness, shortness of breath, arrhythmias or friction rubs;~* Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the study vaccine (includes placebo) or planned use during the study period;~* Planned administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before the first dose of the study vaccine/placebo and ending 30 days after the second dose;~* A planned move to a location that will prohibit participating in the trial for 9 months after the initial vaccination;~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 90 days preceding the first dose or planned administration during the study period. For corticosteroids, this will mean prednisone, or equivalent, 0.5 mg/kg/day. Inhaled and topical steroids are allowed;~* Administration of immunoglobulins and/or blood products within 90 days preceding the first dose or planned administration during the study period;~* Any chronic systemic drug therapy to be continued during the study period (except for vitamin/mineral supplements or routine treatment for gastro-esophageal reflux);~* No easy access to a fixed or mobile telephone

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- T-DEN F17 (Type: EXPERIMENTAL): Full Dose (0.5 mL) 0 and 6 months
- T-DEN F19 (Type: EXPERIMENTAL): Full Dose (0.5 mL) at 0 and 6 months
- Placebo Comparator (Type: PLACEBO_COMPARATOR): 0.5 mL sterile buffer at 0 and 6, subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete